130 related articles for article (PubMed ID: 11179438)
1. A novel approach to thymidylate synthase as a target for cancer chemotherapy.
Li Q; Boyer C; Lee JY; Shepard HM
Mol Pharmacol; 2001 Mar; 59(3):446-52. PubMed ID: 11179438
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.
Neuteboom ST; Karjian PL; Boyer CR; Beryt M; Pegram M; Wahl GM; Shepard HM
Mol Cancer Ther; 2002 Apr; 1(6):377-84. PubMed ID: 12477050
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
Lackey DB; Groziak MP; Sergeeva M; Beryt M; Boyer C; Stroud RM; Sayre P; Park JW; Johnston P; Slamon D; Shepard HM; Pegram M
Biochem Pharmacol; 2001 Jan; 61(2):179-89. PubMed ID: 11163332
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Boyer CR; Karjian PL; Wahl GM; Pegram M; Neuteboom ST
Anticancer Drugs; 2002 Jan; 13(1):29-36. PubMed ID: 11914638
[TBL] [Abstract][Full Text] [Related]
5. Cellular transformation of the investigational new anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2'-deoxyuridine, results in modification of cellular proteins not DNA.
Sergeeva MV; Cathers BE
Biochem Pharmacol; 2003 Mar; 65(5):823-31. PubMed ID: 12628478
[TBL] [Abstract][Full Text] [Related]
6. NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint.
Dellinger RW; Karjian PL; Neuteboom ST
Anticancer Drugs; 2003 Jul; 14(6):449-55. PubMed ID: 12853888
[TBL] [Abstract][Full Text] [Related]
7. Kinetic properties of human thymidylate synthase, an anticancer drug target.
Sergeeva OA; Khambatta HG; Cathers BE; Sergeeva MV
Biochem Biophys Res Commun; 2003 Jul; 307(2):297-300. PubMed ID: 12859954
[TBL] [Abstract][Full Text] [Related]
8. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.
Berg RW; Ferguso PJ; DeMoor JM; Vincen MD; Koropatnick J
Curr Drug Targets; 2002 Aug; 3(4):297-309. PubMed ID: 12102601
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
10. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Giovannetti E; Backus HH; Wouters D; Ferreira CG; van Houten VM; Brakenhoff RH; Poupon MF; Azzarello A; Pinedo HM; Peters GJ
Br J Cancer; 2007 Mar; 96(5):769-75. PubMed ID: 17339891
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen.
Parr AL; Myers TG; Holbeck SL; Loh YJ; Allegra CJ
Anticancer Drugs; 2001 Aug; 12(7):569-74. PubMed ID: 11487712
[TBL] [Abstract][Full Text] [Related]
14. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase: a critical target in cancer therapy?
Rustum YM
Front Biosci; 2004 Sep; 9():2467-73. PubMed ID: 15353299
[TBL] [Abstract][Full Text] [Related]
16. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds.
Schmitz JC; Chen TM; Chu E
Cancer Res; 2004 Feb; 64(4):1431-5. PubMed ID: 14973067
[TBL] [Abstract][Full Text] [Related]
17. Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs.
Jason TL; Berg RW; Vincent MD; Koropatnick J
Gene Expr; 2007; 13(4-5):227-39. PubMed ID: 17605297
[TBL] [Abstract][Full Text] [Related]
18. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
19. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ
Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800
[TBL] [Abstract][Full Text] [Related]
20. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
